Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “bexarotene” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 11
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 11 pipeline programs matching "bexarotene" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

11 results for “bexarotene” Back to intelligence hub

Search results

  1. bexarotene

    Eisai Co.,

    Non-small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial
  2. Bexarotene

    LIGAND PHARMACEUTICALS INC

    Lung Cancer

    phase 2 small molecule completed

    1 trial
  3. Bexarotene

    LIGAND PHARMACEUTICALS INC

    Sarcoma, Kaposi

    phase 2 small molecule completed

    1 trial
  4. Bexarotene (targretin)

    LIGAND PHARMACEUTICALS INC

    Carcinoma, Non-small-cell Lung

    phase 2 small molecule terminated

    1 trial
  5. Bexarotene 1% gel

    LIGAND PHARMACEUTICALS INC

    Parapsoriasis

    phase 2 small molecule terminated

    1 trial
  6. Bexarotene/NBUVB vs placebo NBUVB

    LIGAND PHARMACEUTICALS INC

    Psoriasis

    phase 2 small molecule completed

    1 trial
  7. bexarotene

    LIGAND PHARMACEUTICALS INC

    Cutaneous T-Cell Lymphoma

    phase 2 small molecule completed

    1 trial
  8. bexarotene

    LIGAND PHARMACEUTICALS INC

    Breast Cancer

    phase 2 small molecule completed

    1 trial
  9. erlotinib and bexarotene

    LIGAND PHARMACEUTICALS INC

    Carcinoma, Non-small-cell Lung

    phase 2 small molecule completed

    1 trial
  10. Bexarotene (Targretin®)

    LIGAND PHARMACEUTICALS INC

    Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus)

    phase 1 small molecule completed

    1 trial
  11. erlotinib (Tarceva) and bexarotene (Targretin)

    LIGAND PHARMACEUTICALS INC

    Carcinoma, Non-small-cell Lung

    small molecule completed

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.